1 / 12

Molecular Capabilities in a Combat Support Hospital

Molecular Capabilities in a Combat Support Hospital. Wade K. Aldous, Ph.D. LTC, USA Edgie-Mark Co, Ph.D., M(ASCP), CPT, USA Edward Keen, Ph.D., M(ASCP), CPT USA. Background and Significance.

ashley
Télécharger la présentation

Molecular Capabilities in a Combat Support Hospital

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Molecular Capabilities in a Combat Support Hospital Wade K. Aldous, Ph.D. LTC, USA Edgie-Mark Co, Ph.D., M(ASCP), CPT, USA Edward Keen, Ph.D., M(ASCP), CPT USA

  2. Background and Significance • The 10th Combat Support Hospital (CSH) is a level III medical facility that provides care to military coalition forces, US DoD civilians, contractors and host nationals. • The unit is augmented with a N403 Microbiology-Laboratory Augmentation set, as well as the Joint Biological Agent and Identification System (JBAIDS).

  3. JBAIDS • Field-hardened air thermocycler capable of automated sample analysis for the presence of targeted DNA sequences for the following pathogens • Anthrax • Plague • Tularemia (“Rabbit Fever”) • Q fever • Brucellosis • WE and VE Encephalitis • E. coli O157:H7

  4. JBAIDS • Currently, the instrument is Diagnostic for the identification of Anthrax, Plague and Tularemia. • Only surveillance kits available for all others • Typical TAT for an assay: 3 to 5 hours

  5. Q Fever and H1N1 • H1N1 is a novel swine-like influenza virus • WHO declared H1N1 as a world-wide epidemic • Gold standard for detection and diagnosis is viral culture, but molecular tools are also available • Q fever caused by Coxiella burnetti • Causes unexplained fevers, chills, atypical pneumonias, commonly diagnosed as “fever of unknown origin” • Literature indicates that endemic in Iraq • Gold standard for detection is serology, but takes several months for diagnosis

  6. Q Fever • Human use protocol # MNC-IRAQ-08-003 • Two red top and 2 blue top tubes collected, sera and plasma sent for serology to USAFSAM • JBAIDS assay requires only 800 ml of sample

  7. Data and results • Sample Size = 17 • JBAIDS compared to serology • Sensitivity = 67% • Specificity = 100% • Convalescent serology used as the gold standard

  8. Challenges for Q Fever Assay • Reagent availability in theater • Contamination issues • Dust? • Positive control? • Training/trouble-shooting

  9. H1N1 • Emergency Use Authorization (EUA) • Test (mostly) Rapid Antigen test (RAT) positive samples • Sample requirements • Nasopharyngeal Swabs (NPS) in Viral or Universal Transport Media • Requires 600 ml of transport media

  10. Data and results • Sample size = 96 • RAT sensitivity and specificity to H1N1 compared to RT-PCR • Sensitivity = 100% • Specificity = 22%

  11. Challenges for H1N1 Assay • Reagent availability in theater • Extremely technical • Training/trouble-shooting • Low throughput- only 4 samples per run • Should all negatives be run due to low specificity?

  12. Summary and Recommendations • JBAIDS is a proven platform for the detection of particular pathogens • Validate and fast-track assay FDA-approval for other assays already fielded for instrument (i.e Q fever) • Develop assays for non-biothreat, but endemic pathogens such as malaria and leishmaniasis

More Related